Member Info for Ronnycant

It is AI-based... for now... in a few mere months, they'll have a pretty good picture if it does what it says on the tin in human...

It is still there... try it yourself...

https://www.investormeetcompany.com/meeting/phase-1b-faridoxorubicin-ava6000-salivary-gland-cancer-data-release/presentation.pdf

I think the shareprice will take a small dive today, due to the impatient and underresearched leaving the ship... to recover quickly in the weeks to come... holding tight. This technology works. The deal window has been opened up. Talks can progress to the next stage.

I guess Bella wants to buy a few more on the cheap.

It has been stated that FAP is not being consumed.

To manage expectations... I hope they will fetch 20mio USD.. anything more would be a real bonus. I'm afraid it might be less

Will the IPO-price reflect the current AIM share-validation? In that case, it will be highly dilutive. Let's say (as an example), they want to raise 250 Mio (equivalent to today's market cap), will it be done at equivalent price per share for 50% of the equity?

AVA6000 is dox once in the tumor, but in higher concentration... so...

Whenever I read the word "surely", I shiver...

That is how you obliterate a tumor (when attaching the matching warhead). That level of concentration in tumor is game changing.

Since Novartis is involved with this Fapi-PET scan tech, it makes absolute sense for Novartis to have both the FAPi diagnostics tool in combination with the compatible FAP-driven Precision treatment. Let's hope they share the same view.

It will show unequivocally just how good (or not good) the AVA6000 works... My money is on success.

Some people just love to be deceived... I hope you enjoyed it... AS is out and straight talker CC is in... But but but... the note said...

Saying I was wrong without saying I was wrong... ;-)

Icecool,

Forgive me but what do I read? Phase 1b ;-)

Jezus man... PET is not a subgroup but a scan tech... It's a nice little addition... FAP-PET Scan technology.

Fully agree.. Exciting times! The key for me is to hear that management and CC look very convinced about the tech.

There won't be an Avacta in 2026... It either ran out of cash, or is taken over... no point in stretching yourself thin to try to materialize longterm revenue. Affyxcell is irrelevant, unless you can monetize now and then get the big take-over...

Wyndrum is this chatroom's equivalent of a metastasizing solid tumor. The point of this thread is, I hope they are looking for a buy out from Affyxcell. I wouldn't have a clue what it would be worth for the majority owners, but even anything that gets close to or above 15Mio would strengthen AVACTA's negotiation position, on top of the DX-sale. There is one target only: be able to show that they can get AVA6000 through the clinic via breakthrough, and that they don't need anyone else. That's where the final deal will be struck...

AVACTA will never see the benefit of Affyxcell, unless they sell their stake in the medium term.

Could they consider being bought out of Affyxcell in order to fund the Precision-trials and be in a good negotiation position? I would be in favor. Affyxcell has undoubtedly great potential, but is too far down the line. We need to bring home Precision and get a good buy out price, before we run out of cash.